Article citationsMore>>

Hainsworth, J.D., Meric-Bernstam, F., Swanton, C., Hurwitz, H., Spigel, D.R., Sweeney, C., et al. (2018) Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results from MyPathway, an Openlabel, Phase IIa Multiple Basket Study. Journal of Clinical Oncology, 36, 536-542. https://doi.org/10.1200/JCO.2017.75.3780

has been cited by the following article:

• TITLE: The Breast Enriched HER2 Molecular Subtype-Like Salivary Duct Carcinoma: A Good Response to Novel Targeted Therapy in Two Advanced Disease Cases

  AUTHORS: Kien Hung Do, Tu Anh Do, Duc Thanh Le, Tai Van Nguyen, Chu Van Nguyen

  KEYWORDS: SDC, Targeted Therapy, HER2 Subtype

  JOURNAL NAME: Open Access Library Journal, Vol.9 No.8, August 19, 2022

  ABSTRACT: Background: Salivary duct carcinoma (SDC) is one of the most aggressive malignant salivary gland tumors resembling high-grade mammary ductal carcinoma, with frequent local recurrence and regional lymph node and distant metastasis. SDC is often the absence of estrogen receptor and progesterone receptor, and Her2/neu overexpression. Treatment with molecular targeted therapy correlated well with long-term survival and therapeutic response in SDC patients. Purpose: We presented the clinicopathologic entity and treatment response of the two cases in Vietnam, firstly and compared it with the related literature to raise awareness of this tumor. Methods: The clinicopathological characteristics of two SDCs were recorded. Immunohistochemical staining was performed on ER, PR, HER2, and some markers. All SDC patients’ treatment responses and survival were accessed. Results and Conclusion: Two men with salivary carcinoma were classified into the breast enriched HER2 molecular subtype-like salivary duct carcinoma in an advanced stage, who have got the molecular targeted therapy as anti-HER2 combined with chemotherapy. They displayed a good response to novel targeted therapy.